Plain-English translation of NCT04752826 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This study is testing a new medication called , which is designed to boost your immune system's ability to fight cancer. Researchers want to see if it works better on its own or when combined with an existing cancer drug called Keytruda. The trial will first find the safest and most effective dose, then test it in larger groups of patients with specific cancer types.
Many people with advanced cancers run out of treatment options when standard therapies stop working. This medication targets a different part of the immune system than current drugs do, so it may help patients who have already tried other treatments.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly for check-ups, blood tests, and scans to monitor how your cancer responds to treatment. Before starting, you'll have a tumor biopsy taken to help doctors understand your specific cancer. Depending on which part of the study you join, you'll receive either the new medication alone or combined with Keytruda through infusions, typically over several months while researchers track your progress.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Denmark